Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Cancer Res

Retrieve available abstracts of 31 articles:
HTML format

Single Articles

    April 2024
  1. BOET E, Sarry JE
    Targeting Metabolic Dependencies Fueling the TCA Cycle to Circumvent Therapy Resistance in Acute Myeloid Leukemia.
    Cancer Res. 2024;84:950-952.
    PubMed     Abstract available

    February 2024
  2. JIN P, Wang X, Jin Q, Zhang Y, et al
    Mutant U2AF1-induced mis-splicing of mRNA translation genes confers resistance to chemotherapy in acute myeloid leukemia.
    Cancer Res. 2024 Feb 28. doi: 10.1158/0008-5472.CAN-23-2543.
    PubMed     Abstract available

  3. LIU ZS, Sinha S, Bannister M, Song A, et al
    R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts.
    Cancer Res. 2024;84:577-597.
    PubMed     Abstract available

    January 2024
  4. MONTEITH AJ, Ramsey HE, Silver AJ, Brown D, et al
    Lactate utilization enables metabolic escape to confer resistance to BET inhibition in acute myeloid leukemia.
    Cancer Res. 2024 Jan 29. doi: 10.1158/0008-5472.CAN-23-0291.
    PubMed     Abstract available

  5. SU Y, Carter JL, Li X, Fukuda Y, et al
    The imipridone ONC213 targets alpha-ketoglutarate dehydrogenase to induce mitochondrial stress and suppress oxidative phosphorylation in acute myeloid leukemia.
    Cancer Res. 2024 Jan 24. doi: 10.1158/0008-5472.CAN-23-2659.
    PubMed     Abstract available

  6. RAUCCI F, Vernieri C, Di Tano M, Ligorio F, et al
    Cyclic fasting-mimicking diet plus bortezomib and rituximab is an effective treatment for chronic lymphocytic leukemia.
    Cancer Res. 2024 Jan 19. doi: 10.1158/0008-5472.CAN-23-0295.
    PubMed     Abstract available

  7. WANG P, Zhang Y, Xiang R, Yang J, et al
    Foretinib is effective in acute myeloid leukemia by inhibiting FLT3 and overcoming secondary mutations that drive resistance to quizartinib and gilteritinib.
    Cancer Res. 2024 Jan 17. doi: 10.1158/0008-5472.CAN-23-1534.
    PubMed     Abstract available

    December 2023
  8. MAI S, Hodges A, Chen HM, Zhang J, et al
    LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy.
    Cancer Res. 2023;83:4047-4062.
    PubMed     Abstract available

  9. XIA L, Liu JY, Yang MY, Zhang XH, et al
    Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells.
    Cancer Res. 2023 Dec 14. doi: 10.1158/0008-5472.CAN-23-1632.
    PubMed     Abstract available

    October 2023
  10. MODI A, Lopez G, Conkrite KL, Su C, et al
    Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors.
    Cancer Res. 2023;83:3462-3477.
    PubMed     Abstract available

    September 2023
    p53 and Innate Immune Signaling in Development and Cancer: Insights from a Hematologic Model of Genome Instability.
    Cancer Res. 2023;83:2807-2808.
    PubMed     Abstract available

  12. DRESSEL N, Natusch L, Munz CM, Costas Ramon S, et al
    Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis.
    Cancer Res. 2023;83:2858-2872.
    PubMed     Abstract available

    August 2023
  13. JONES CL
    Turning Down the Temperature on Leukemia Stem Cells.
    Cancer Res. 2023;83:2441-2442.
    PubMed     Abstract available

    June 2023
  14. FARGE T, Nakhle J, Lagarde D, Cognet G, et al
    CD36 drives metastasis and relapse in acute myeloid leukemia.
    Cancer Res. 2023 Jun 16:CAN-22-3682. doi: 10.1158/0008-5472.CAN-22-3682.
    PubMed     Abstract available

  15. GRIESSINGER E, Pereira-Martins D, Nebout M, Bosc C, et al
    Oxidative phosphorylation fueled by fatty acid oxidation sensitizes leukemic stem cells to cold.
    Cancer Res. 2023 Jun 5:CAN-23-1006. doi: 10.1158/0008-5472.CAN-23-1006.
    PubMed     Abstract available

    May 2023
  16. SEKHAR KR, Freeman ML
    Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment.
    Cancer Res. 2023;83:1573-1580.
    PubMed     Abstract available

    January 2023
  17. CHAMBERS C, Cermakova K, Chan YS, Kurtz K, et al
    SWI/SNF blockade disrupts PU.1-directed enhancer programs in normal hematopoietic cells and acute myeloid leukemia.
    Cancer Res. 2023 Jan 20:CAN-22-2129. doi: 10.1158/0008-5472.CAN-22-2129.
    PubMed     Abstract available

  18. HONG YG, Yang Z, Chen Y, Liu T, et al
    The RNA m6A reader YTHDF1 is required for acute myeloid leukemia progression.
    Cancer Res. 2023 Jan 12:CAN-21-4249. doi: 10.1158/0008-5472.CAN-21-4249.
    PubMed     Abstract available

    November 2022
  19. ZHU LY, Yuan JB, Zhang L, He CX, et al
    Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis.
    Cancer Res. 2022;82:4153-4163.
    PubMed     Abstract available

    September 2022
  20. LIU ACH, Cathelin S, Yang Y, Dai DL, et al
    Targeting STAT5 signaling overcomes resistance to IDH inhibitors in acute myeloid leukemia through suppression of stemness.
    Cancer Res. 2022 Sep 23. pii: 709375. doi: 10.1158/0008-5472.CAN-22-1293.
    PubMed     Abstract available

    August 2022
  21. HNATIUK AP, Bruyneel AAN, Tailor D, Pandrala M, et al
    Reengineering Ponatinib to Minimize Cardiovascular Toxicity.
    Cancer Res. 2022;82:2777-2791.
    PubMed     Abstract available

    June 2022
  22. PFEIFFER A, Franciosa G, Locard-Paulet M, Piga I, et al
    Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.
    Cancer Res. 2022;82:2141-2155.
    PubMed     Abstract available

    March 2022
  23. CASADO-GARCIA A, Isidro-Hernandez M, Oak N, Mayado A, et al
    Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice.
    Cancer Res. 2022;82:1098-1109.
    PubMed     Abstract available

  24. BRAUN T, Stachelscheid J, Bley N, Oberbeck S, et al
    Non-canonical function of AGO2 augments T-cell receptor signaling in T-cell prolymphocytic leukemia.
    Cancer Res. 2022 Mar 8. pii: 682091. doi: 10.1158/0008-5472.CAN-21-1908.
    PubMed     Abstract available

    December 2021
  25. PORAZZI P, Petruk S, Pagliaroli L, De Dominici M, et al
    Targeting chemotherapy to de-condensed H3K27me3-marked chromatin of AML cells enhances leukemia suppression.
    Cancer Res. 2021 Dec 13. pii: 0008-5472.CAN-21-1297.
    PubMed     Abstract available

    October 2021
  26. BIRAN A, Yin S, Kretzmer H, Ten Hacken E, et al
    Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia.
    Cancer Res. 2021 Oct 22. pii: 0008-5472.CAN-21-1273.
    PubMed     Abstract available

  27. GOLDBERG L, Negi V, Chung YJ, Onozawa M, et al
    Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL.
    Cancer Res. 2021;81:5033-5046.
    PubMed     Abstract available

    September 2021
  28. SANJIV K, Calderon-Montano JM, Pham TM, Erkers T, et al
    MTH1 inhibitor TH1579 induces oxidative DNA damage and mitotic arrest in acute myeloid leukemia.
    Cancer Res. 2021 Sep 30. pii: 0008-5472.CAN-21-0061.
    PubMed     Abstract available

    July 2021
  29. MAIFREDE S, Le BV, Nieborowska-Skorska M, Golovine K, et al
    TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors.
    Cancer Res. 2021 Jul 2. pii: 0008-5472.CAN-20-3761.
    PubMed     Abstract available

    February 2021
  30. O'HAGAN HM, Rassool FV, Nephew KP
    How Epigenetic Therapy Beats Adverse Genetics in Monosomy Karyotype AML.
    Cancer Res. 2021;81:813-815.
    PubMed     Abstract available

  31. GREVE G, Schuler J, Gruning BA, Berberich B, et al
    Decitabine Induces Gene Derepression on Monosomic Chromosomes: In Vitro and In Vivo Effects in Adverse-Risk Cytogenetics AML.
    Cancer Res. 2021;81:834-846.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.